share_log

3SBio (HKG:1530) Ticks All The Boxes When It Comes To Earnings Growth

3SBio (HKG:1530) Ticks All The Boxes When It Comes To Earnings Growth

在收益增長方面,3sBio(HKG: 1530)勾選了所有方框
Simply Wall St ·  2023/12/07 17:02

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.

對於初學者來說,收購一家向投資者講述好故事的公司似乎是個好主意(也是一個令人興奮的前景),即使該公司目前缺乏收入和利潤記錄。不幸的是,這些高風險投資通常幾乎沒有回報的可能性,許多投資者爲吸取教訓付出了代價。虧損的公司尚未通過利潤證明自己,最終外部資本的流入可能會枯竭。

Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like 3SBio (HKG:1530). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing.

儘管處於科技股藍天投資時代,但許多投資者仍然採用更傳統的策略:購買3sBio(HKG: 1530)等盈利公司的股票。儘管這並不一定說明其估值是否被低估,但該業務的盈利能力足以保證一定的升值——尤其是在其增長的情況下。

Check out our latest analysis for 3SBio

查看我們對 3sBio 的最新分析

How Fast Is 3SBio Growing?

3sBio 的增長速度有多快?

If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. We can see that in the last three years 3SBio grew its EPS by 15% per year. That's a good rate of growth, if it can be sustained.

如果你認爲市場的效率甚至含糊不清,那麼從長遠來看,你預計公司的股價將遵循其每股收益(EPS)的結果。因此,有很多投資者喜歡購買每股收益不斷增長的公司的股票。我們可以看到,在過去三年中,3sBio的每股收益每年增長15%。如果可以持續的話,這是一個不錯的增長率。

It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. 3SBio shareholders can take confidence from the fact that EBIT margins are up from 26% to 31%, and revenue is growing. Ticking those two boxes is a good sign of growth, in our book.

查看利息和稅前收益(EBIT)利潤率以及收入增長通常很有幫助,這樣可以重新了解公司的增長質量。3sBio的股東可以從息稅前利潤率從26%上升到31%,收入正在增長這一事實中獲得信心。在我們的書中,勾選這兩個方框是增長的好兆頭。

The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.

下圖顯示了該公司的收入和收入隨着時間的推移是如何發展的。要了解更多細節,請點擊圖片。

earnings-and-revenue-history
SEHK:1530 Earnings and Revenue History December 7th 2023
SEHK: 1530 2023 年 12 月 7 日的收益和收入歷史記錄

While we live in the present moment, there's little doubt that the future matters most in the investment decision process. So why not check this interactive chart depicting future EPS estimates, for 3SBio?

雖然我們生活在當下,但毫無疑問,未來在投資決策過程中最重要。那麼,爲什麼不查看這張描繪3sBio未來每股收益估計值的交互式圖表呢?

Are 3SBio Insiders Aligned With All Shareholders?

3sBio Insiders 是否與所有股東保持一致?

It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. 3SBio followers will find comfort in knowing that insiders have a significant amount of capital that aligns their best interests with the wider shareholder group. We note that their impressive stake in the company is worth CN¥1.1b. This suggests that leadership will be very mindful of shareholders' interests when making decisions!

公司領導者必須爲股東的最大利益行事,因此內幕投資始終是市場的保證。3sBio的追隨者知道內部人士擁有與更廣泛的股東群體的最佳利益相一致的大量資本,他們會感到安慰。我們注意到,他們在該公司的可觀股份價值11億元人民幣。這表明領導層在做出決策時會非常注意股東的利益!

Does 3SBio Deserve A Spot On Your Watchlist?

3sBio 值得在您的關注清單上佔有一席之地嗎?

As previously touched on, 3SBio is a growing business, which is encouraging. For those who are looking for a little more than this, the high level of insider ownership enhances our enthusiasm for this growth. The combination definitely favoured by investors so consider keeping the company on a watchlist. While we've looked at the quality of the earnings, we haven't yet done any work to value the stock. So if you like to buy cheap, you may want to check if 3SBio is trading on a high P/E or a low P/E, relative to its industry.

如前所述,3sBio是一項成長中的業務,這令人鼓舞。對於那些追求更多收益的人來說,高水平的內部所有權增強了我們對這種增長的熱情。這種組合肯定受到投資者的青睞,因此可以考慮將公司保留在觀察名單上。儘管我們已經研究了收益質量,但我們還沒有爲股票估值做任何工作。因此,如果你想以低廉的價格購買,你可能需要檢查3sBio相對於其行業是高市盈率還是低市盈率。

The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.

投資的好處在於,你幾乎可以投資任何你想要的公司。但是,如果你更願意關注表現出內幕買盤的股票,以下是過去三個月內有內幕買盤的公司名單。

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

請注意,本文中討論的內幕交易是指相關司法管轄區內應報告的交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論